Liver Disorders
An Introduction to Liver Disorders
Hepatology covers hepatitis, hepatocellular carcinoma (HCC), nonalcoholic fatty liver disease (NAFLD), cirrhosis and rarer conditions such as autoimmune and cholestatic liver diseases. Despite numerous advances, liver-related mortality has remained stable for over 30 years. The World Health Organization has set targets for hepatitis C elimination by 2030. Immunotherapy and combination therapies have greatly increased the efficacy of the treatment of hepatocellular carcinoma (HCC). However, as a result of the increasing prevalence of obesity, NAFLD is reaching epidemic proportions and poses a major challenge to global public health. There is an urgent need for long-term management strategies and pharmacological interventions for NAFLD.
Our supporting partners do not constitute an endorsement of the content on this page.
Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive liver disease driven by fat build-up and immune activation, often linked to obesity and diabetes. Emerging therapies target both metabolic and immune pathways, showing promise in reducing inflammation, improving liver function, and reversing fibrosis. These advances offer hope for better management of this complex disease.
In this Future Leaders interview, Dr Moritz Peiseler shares how his work is reshaping our understanding of liver immunity through tools like intravital microscopy and AI-driven data analysis. He highlights the adaptive nature of immune cells in fibrotic tissue, the critical value of the clinician-scientist role, and the emerging potential of spatial and single-cell technologies. Dr Peiseler also offers thoughtful advice for young researchers aiming to bridge science and patient care.
In this interview, EASL Secretary General Professor Debbie Shawcross discusses the growing burden of liver disease across Europe and the urgent need for early diagnosis, equitable care, and patient-centred approaches. She highlights how EASL is tackling these challenges through education, research, advocacy, and initiatives that bridge innovation and clinical practice to improve outcomes in hepatology.
As touchIMMUNOLOGY approaches 20 years of providing education for busy immunologists, we are looking to the future—and it certainly looks bright!
Physician burnout is at a critical point. In this episode, Nicky speaks with Dr Alfred Atanda about why so many physicians are burning out and what can be done to change the trend. From personal experience to system-wide solutions, Dr Atanda shares valuable insights on improving physician well-being and building a more effective healthcare culture.
What if your medical degree could launch more than a clinical career? In this candid and compelling read, Dr Jon Edelson shares his lessons for early-career doctors ready to think beyond the bedside and explore the business of medicine.
In this episode, we explore the future of continuing medical education (CME) with the team behind touchIME. Hannah Fisher and Matthew Goodwin share insights into global and US trends, the importance of patient inclusivity and how educational outcomes are evolving to better measure the direct impact of learning on clinical practice and patient care.
Findings from the Spring Study – CM-101 for Primary Sclerosing Cholangitis: Paul Pockros, DDW 2025
In the interview, Dr Paul Pockros discusses his presentation from DDW 2025 on the SPRING study (NCT04595825), which evaluated CM-101, a novel anti-CCL24 monoclonal antibody, in adults with primary sclerosing cholangitis (PSC). With no FDA-approved treatments for PSC, CM-101 showed promising safety, tolerability, and biomarker improvements over 48 weeks, supporting advancement to phase 3 trials.
The EASL 2024 meeting offered a great opportunity for hepatologists from around the world to discuss the latest data and tackle challenges in liver disease. Metabolic dysfunction-associated steatohepatitis (MASH) was a hot topic, with several exciting studies making waves. This article ...
LIBERTY-EoE-TREET (NCT03633617) was a phase 3, randomized, 3-part study investigating the efficacy and safety of dupilumab in eosinophilic esophagitis (EoE). It was a pleasure to talk with Prof. Arjan Bredenoord (Amsterdam UMC, Amsterdam, the Netherlands) around his analysis of the LIBERTY-EoE-TREET ...
MYR301 (NCT03852719) is a phase 3 study evaluating the long-term efficacy and safety of bulevirtide in people living with chronic hepatitis delta infection (CHD). In this interview, Prof. Maria Buti (Vall d'Hebron University Hospital, Barcelona, Spain) discusses the results from the ...
touchIMMUNOLOGY spoke with Prof. Thomas Berg (University Hospital Leipzig, Leipzig, Germany; Secretary General, EASL) to discuss the burden of hepatitis, the path to diagnosis, and the current treatment options available for hepatitis B, C, and D. Question: What are the ...
It was a pleasure to speak with Prof. Nancy Reau (Rush Medical College, Chicago, IL, USA) about the hepatic manifestations of COVID-19 infection. Her presentation entitled ‘HEPATIC MANIFESTATIONS OF COVID-19: IS THERE CAUSE FOR CONCERN?’ was given at DDW, 21-23 ...
In Part 2 of our ACR Convergence Highlights coverage, Peter C Taylor (University of Oxford, Oxford, UK) discusses the results of an exploratory study into the association of Hydroxychloroquine (HCQ) use and the development of Non-Alcoholic Fatty Liver Disease (NAFLD) in ...
Log into your Touch Account
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Sign up with an Email
Or use a .
This Functionality is for
Members Only
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
